title: Severe protein C deficiency predicts early death in severe sepsis.
abstract: OBJECTIVE
  To explore the relationship between measures of baseline disease severity and survival time in patients with severe sepsis.
  
  
  METHODS
  A retrospective evaluation of the placebo group from a large placebo-controlled phase III clinical trial (PROWESS) comprising a total of 840 patients with severe sepsis from 164 medical centers.
  
  
  METHODS
  Data collected included baseline demographics and disease severity measurements, baseline protein C and interleukin-6 levels, 28-day and in-hospital survival rates, and cause of death to 28 days. The survival curve for the placebo patients can be divided into three segments during which the rate of death seemed to be different: the rapid alpha phase (day 0 to day 5), the beta phase (day 6 through day 15), and the gamma phase (day 16 to day 28). The risk of death during each phase was statistically significantly different. More patients died of refractory shock during the alpha phase than in the beta and gamma phases, whereas more patients died of respiratory failure during the beta and gamma phases than during the alpha phase. Multiple organ failure was a frequent cause of death during all phases. Protein C levels at the start of each time interval were highly predictive of outcome within that phase, with continued protein C deficiency being associated with mortality. Patients who died during either the alpha or beta phases had higher interleukin-6 levels at baseline than those who died later or who eventually survived.
  
  
  CONCLUSIONS
  The rate and cause of death for patients with severe sepsis differs during the 28-day postdiagnosis period. Severe protein C deficiency (<40% of the level of protein C in pooled normal human plasma) and high interleukin-6 levels were associated with early death that resulted predominantly from refractory shock and multiple organ dysfunction.
authors.affiliation: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA. wlm@lilly.com
authors.forename: William L
authors.initials: WL
authors.lastname: Macias
authors.forename: David R
authors.initials: DR
authors.lastname: Nelson
mesh_terms: D002423:Cause of Death; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D011379:Prognosis; D020151:Protein C Deficiency / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D018805:Sepsis / Q000150:complications* / Q000401:mortality*; D012720:Severity of Illness Index; D015996:Survival Rate; D013997:Time Factors